Peptide LibraryResearch statistics
Degarelix research: publications and trials
At a glance
Publications, all years
308
Since 2001
Publications in 2026 so far
18
Through November 1, 2026
Human clinical research
50.3%
155 of 308 classified
Registered clinical trials
144
ClinicalTrials.gov
Randomized controlled trials
50
Publications reporting an RCT in people
Systematic reviews and meta-analyses
13
Preclinical studies
21.4%
46 animal · 9 in vitro · 11 computational
Records that only mention it
67
Not counted above
Status in the library: FDA-approved.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Degarelix publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2001 | 1 | 0 | 0 | 0 | 1 |
| 2002 | 0 | 1 | 0 | 0 | 1 |
| 2003 | 0 | 2 | 0 | 0 | 2 |
| 2004 | 0 | 3 | 0 | 0 | 3 |
| 2005 | 0 | 2 | 0 | 0 | 2 |
| 2006 | 1 | 3 | 1 | 0 | 5 |
| 2007 | 0 | 1 | 0 | 0 | 1 |
| 2008 | 3 | 0 | 2 | 2 | 7 |
| 2009 | 2 | 0 | 11 | 1 | 14 |
| 2010 | 1 | 1 | 3 | 1 | 6 |
| 2011 | 6 | 3 | 2 | 1 | 12 |
| 2012 | 7 | 1 | 7 | 1 | 16 |
| 2013 | 6 | 0 | 2 | 0 | 8 |
| 2014 | 5 | 2 | 5 | 2 | 14 |
| 2015 | 11 | 4 | 3 | 1 | 19 |
| 2016 | 9 | 4 | 6 | 1 | 20 |
| 2017 | 7 | 2 | 3 | 1 | 13 |
| 2018 | 11 | 8 | 2 | 0 | 21 |
| 2019 | 8 | 1 | 1 | 1 | 11 |
| 2020 | 10 | 3 | 0 | 3 | 16 |
| 2021 | 15 | 6 | 5 | 3 | 29 |
| 2022 | 11 | 3 | 3 | 2 | 19 |
| 2023 | 8 | 7 | 1 | 0 | 16 |
| 2024 | 6 | 3 | 3 | 0 | 12 |
| 2025 | 14 | 3 | 5 | 0 | 22 |
| 2026 (to date) | 13 | 3 | 2 | 0 | 18 |
Study types
| Review | 54 |
|---|---|
| Randomized controlled trial | 50 |
| Observational human study | 47 |
| Animal study | 46 |
| Other clinical trial | 30 |
| Case report | 28 |
| Editorial, letter or other | 18 |
| Computational study | 11 |
| In vitro study | 9 |
| Meta-analysis | 9 |
| Systematic review | 4 |
| Correction or retraction notice | 2 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Oncology | 248 |
|---|---|
| Reproductive and sexual health | 192 |
| Endocrinology | 56 |
| Cardiovascular | 38 |
| Metabolic health | 15 |
| Neurological and mental health | 15 |
| Musculoskeletal | 12 |
| Dermatology | 7 |
| Immune system | 7 |
| Antimicrobial and infectious disease | 5 |
| Tissue repair | 4 |
| Gastrointestinal | 3 |
Registered clinical trials
25 of 75 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 76 · Active, not recruiting: 18 · Recruiting: 18 · Terminated: 14 · Unknown status: 11 · Withdrawn: 6 · Not yet recruiting: 1
Early phase 1: 3 · Phase not applicable: 23 · Phase 1: 6 · Phase 1 / Phase 2: 5 · Phase 2: 61 · Phase 2 / Phase 3: 6 · Phase 3: 31 · Phase 4: 9
The 50 most recently started of 144 trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Effectiveness and safety of degarelix compared to GnRH agonists for prostate cancer: a systematic review and meta-analysis.
The aging male : the official journal of the International Society for the Study of the Aging Male · November 11, 2025 · Meta-analysis · cited 5 times · open access
PMID 41216753 · DOI 10.1080/13685538.2025.2581656 · Reviews and meta-analyses
- Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis.
Urologic oncology · January 16, 2025 · Meta-analysis · cited 4 times
PMID 39818461 · DOI 10.1016/j.urolonc.2024.12.277 · Reviews and meta-analyses
- A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · November 5, 2024 · Meta-analysis · cited 5 times
PMID 39500846 · DOI 10.1007/s12094-024-03772-2 · Reviews and meta-analyses
- Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies.
European urology oncology · September 28, 2024 · Meta-analysis · cited 6 times · open access
PMID 39343637 · DOI 10.1016/j.euo.2024.09.004 · Reviews and meta-analyses
- Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · July 23, 2019 · Meta-analysis · cited 11 times · open access
PMID 31348745 · DOI 10.5489/cuaj.5996 · Reviews and meta-analyses
- A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.
Medicine · July 1, 2016 · Meta-analysis · cited 57 times · open access
PMID 27399062 · DOI 10.1097/md.0000000000003845 · Reviews and meta-analyses
- Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.
Medical journal of the Islamic Republic of Iran · January 9, 2016 · Meta-analysis · cited 16 times · open access
PMID 27390687 · Reviews and meta-analyses
- Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Urologia internationalis · March 1, 2014 · Meta-analysis · cited 27 times
PMID 24603064 · DOI 10.1159/000356272 · Reviews and meta-analyses
- Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
European urology · January 9, 2014 · Meta-analysis · cited 108 times
PMID 24440304 · DOI 10.1016/j.eururo.2013.12.063 · Reviews and meta-analyses
- The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
European heart journal. Cardiovascular pharmacotherapy · May 1, 2022 · Systematic review · cited 41 times
PMID 33470403 · DOI 10.1093/ehjcvp/pvab005 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
BJU international · December 1, 2008 · Randomized controlled trial · cited 615 times · open access
PMID 19035858 · DOI 10.1111/j.1464-410x.2008.08183.x · Human clinical research
- A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Clinical cancer research : an official journal of the American Association for Cancer Research · July 1, 2007 · Animal study · cited 422 times
PMID 17606733 · DOI 10.1158/1078-0432.ccr-07-0078 · Animal studies
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Circulation · August 30, 2021 · Randomized controlled trial · cited 155 times · open access
PMID 34459214 · DOI 10.1161/circulationaha.121.056810 · Human clinical research
- Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
The Journal of pharmacology and experimental therapeutics · April 1, 2002 · Animal study · cited 152 times · open access
PMID 11907162 · DOI 10.1124/jpet.301.1.95 · Animal studies
- A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
The Journal of urology · July 23, 2011 · Randomized controlled trial · cited 152 times
PMID 21788033 · DOI 10.1016/j.juro.2011.04.083 · Human clinical research
Latest publications
- Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.
Urologic oncology · October 18, 2026 · Observational human study · cited 0 times
PMID 42892580 · DOI 10.1016/j.urolonc.2026.09.012 · Human clinical research
- Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · September 14, 2026 · Other clinical trial · cited 0 times · open access
PMID 42733361 · DOI 10.1080/02656736.2026.2716351 · Human clinical research
- A novel model to study the impact of gender-affirming therapy on bone in young male mice.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · August 1, 2026 · Animal study · cited 0 times · open access
PMID 41543142 · DOI 10.1093/jbmr/zjag009 · Animal studies
- Prostate cancer-associated Trousseau's syndrome presenting as stroke in a 42-year-old man.
Urology case reports · July 10, 2026 · Case report · cited 0 times · open access
PMID 42518671 · DOI 10.1016/j.eucr.2026.103542 · Human clinical research
- Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report.
Frontiers in medicine · May 29, 2026 · Case report · cited 0 times · open access
PMID 42292172 · DOI 10.3389/fmed.2026.1718567 · Human clinical research
- Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.
Cancer chemotherapy and pharmacology · May 20, 2026 · Case report · cited 0 times
PMID 42159776 · DOI 10.1007/s00280-026-04903-y · Human clinical research
- Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.
International urology and nephrology · May 19, 2026 · Observational human study · cited 1 times
PMID 42154420 · DOI 10.1007/s11255-026-05205-1 · Human clinical research
- Dual case insights shaping a new protocol for post-menopausal hirsutism.
JCEM case reports · May 6, 2026 · Case report · cited 0 times · open access
PMID 42100586 · DOI 10.1210/jcemcr/luag087 · Human clinical research
- Adverse Event Reporting Patterns Associated with Degarelix and Relugolix: A Pharmacovigilance Study Based on the FAERS Database.
Urologia internationalis · April 17, 2026 · Observational human study · cited 0 times
PMID 41996296 · DOI 10.1159/000551870 · Human clinical research
- Resting state functional connectivity in paedophilic disorder and degarelix treatment.
Acta neuropsychiatrica · April 1, 2026 · Randomized controlled trial · cited 0 times · open access
PMID 41918172 · DOI 10.1017/neu.2026.10073 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Degarelix; FE200486; Firmagon
((TITLE_ABS:"Degarelix" OR CHEM:"Degarelix") OR (TITLE_ABS:"FE200486" OR CHEM:"FE200486" OR TITLE_ABS:"FE 200486" OR CHEM:"FE 200486") OR (TITLE_ABS:"Firmagon" OR CHEM:"Firmagon")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Degarelix research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/degarelix